Pradofloxacin

From Self-sufficiency
Jump to: navigation, search
Pradofloxacin
File:Pradofloxacin.png
Systematic (IUPAC) name
8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydoquinoline-3-carboxylic acid
Identifiers
ATC code none
PubChem CID 9802884
Chemical data
Formula C21H21FN4O3
Molar mass 396.414 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pradofloxacin (tradename Veraflox) is a quinolone antibiotic developed by Bayer AG, intended to treat infections in dogs and cats. The European Medicines Agency refused to grant marketing authorization for Veraflox, citing product safety and quality issues.[1]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Antifolates
(inhibits
purine metabolism,
thereby inhibiting
DNA and RNA synthesis)
Other/ungrouped
Combinations
Topoisomerase
inhibitors/
quinolones/
(inhibits
DNA replication)
Related agents (DG)
Anaerobic DNA
inhibitors
Nitro- imidazole derivatives
Nitrofuran derivatives
RNA synthesis

M: BAC

drug(J1p, w, n, m, vacc)


50px This systemic antibacterial-related article is a stub. You can help ssf by expanding it.
  1. ↑ European Medicines Agency (2007). REFUSAL CHMP ASSESSMENT REPORT FOR VERAFLOX. Procedure No. EMEA/V/C/099PDF (279 KB). London: European Medicines Agency. Retrieved on 2008-06-23. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Pradofloxacin&oldid=23468"